Skip to content
OpenCapital
Get started

Arbutus Biopharma Corporation ABUS Cash Equivalents, Fair Value Disclosure

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$871.14M+32.6%
Enterprise value$848.07M+36.6%
P/E5.4×—
P/S4.6×-98.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept abus:CashEquivalentsFairValueDisclosure.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's cash equivalents, fair value disclosure.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's cash equivalents, fair value disclosure?
Arbutus Biopharma Corporation (ABUS) reported cash equivalents, fair value disclosure of $14.49M in Q1 2026.
How has Arbutus Biopharma Corporation's cash equivalents, fair value disclosure changed year-over-year?
Arbutus Biopharma Corporation's cash equivalents, fair value disclosure decreased by 45.1% year-over-year, from $26.38M to $14.49M.